Organic Active Ingredients TRIZ Cases

A maleate salt of a cyclohexane derivative reduces hygroscopicity through ionic bonding and crystal structure stabilization.

A miRNA-342 molecule regulates gene expression to induce anti-tumor activity in squamous cell carcinoma.

Segmented nifedipine liquid dosage units reduce maternal adverse effects while maintaining tocolytic efficacy.

Replacing invasive surgery, a CBX7 inhibitor treats cerebral cavernous malformations by targeting epigenetic regulators to prevent lesion progression.

Low dose radiation elicits repair mechanisms in non-neoplastic cells, reducing damage to surrounding healthy tissues during cancer therapy.

A Cas9 nickase paired with a 3' to 5' exonuclease processes DNA overhangs to generate precise deletions in target nucleic acids.

Polyvinylpyrrolidone balances tablet hardness against dispersion time, resolving the contradiction between mechanical strength and rapid dissolution.

Modified VWF-targeting aptamers use nucleotide changes and PEGylation to enhance nuclease stability and circulation time.

Segmenting adenosine receptor activity into selective A2A antagonism reduces vascular complications while treating movement disorders.

Antisense oligomers hybridize with interleukin pre-mRNA to alter splicing, resolving inadequate immune therapy specificity.

Carbonate prodrug derivatives of psilocin overcome synthesis complexity and oxidation instability by enabling controlled hydrolysis to release active compounds.

Low-temperature enzymatic extraction preserves volatile compounds while increasing bioavailability to treat skin diseases without steroid-induced atrophy.

Measuring ribosomal protein expression levels identifies glioblastoma patients likely to respond to toxic topoisomerase poisons, avoiding ineffective treatment.

Novel bicyclic urea compounds bypass the stratum corneum barrier to induce melanin production without UV irradiation.

Formula I small organic molecules inhibit C5aR-mediated chemotaxis and anaphylatoxic activity for autoimmune disease treatment.

Administering clemizole or R-chloroquine reduces lobular inflammation and steatosis in non-alcoholic steatohepatitis.

Engineered extracellular vesicles display dual antigen-binding domains to activate immune cells and promote immunological synapse formation.

Optimized drospirenone particle sizes and skipped-dose regimens reduce plasma peaks while maintaining contraceptive efficacy.

A rotating turret supplies multiple die placement heads to a force application rod, eliminating head swapping delays and reducing cycle time.

Monitoring morning cortisol and ACTH concentrations enables prophylactic mineralocorticoid treatment to prevent life-threatening cardiac arrhythmias.

FGF21 agents stimulate oligodendrocyte precursor cell proliferation to regenerate damaged myelin sheaths in the central nervous system.

Segmenting TMC278 into nanoparticles creates a depot effect that maintains viral suppression while reducing dosing frequency and resistance risk.

Macrocyclic compounds modify chemical structures to inhibit hepatitis C virus replication while improving metabolic stability and reducing side effects.

Composite bacterial cellulose film with moisturizing agents resolves the trade-off between high liquid content and structural stability in eye patches.

Quinazoline-2,4-dione derivatives inhibit TRPC5-mediated ion flux to treat neuropsychiatric disorders.

A corticosteroid dispensing system qualifies patients via surveys and phone screening before medication release.

Tartrate salts of quinazoline compounds with zinc-binding moieties enhance solubility and stability for pharmaceutical delivery.

Segmented benzimidazole hexahydrofuro[3,2-b]furan derivatives activate AMPK to improve insulin resistance while reducing side effects.

Compacted nutrient pellets use sequential organic solvent and fatty acid salt coatings to form a protective barrier around the central core.

Soluble substrate coating dissolves in liquid to deliver precise doses while color change confirms complete absorption.

Modifying adenosine structures reduces toxicity while maintaining enzyme inhibition, overcoming limitations of existing cancer therapies.

Combines hyaluronic acid with bone morphogenetic protein for intra-articular injection to promote cartilage regeneration.

Pyridine mediates CPT-11 condensation at room temperature, stabilizing intermediates to resolve low yield and impurity issues.

Merging STAT3 antisense inhibition with PD-L1 blockade overcomes immunosuppressive barriers that limit single-agent efficacy.

Substituted azole dione compounds abrogate the G2 checkpoint, forcing DNA-damaged cancer cells into mitotic catastrophe while sparing normal cells.

Transdermal delivery system with abuse deterrent agents minimizes plasma spikes and side effects while maintaining sustained therapeutic efficacy.

AAV vectors cross the blood-brain barrier to express TPP1, bypassing systemic delivery limits.

Segmented hydrophobic and hydrophilic matrices prevent chemical instability between celecoxib and acetaminophen while maintaining rapid dissolution.

A wearable grid stimulates specific nocipoints to trigger a neuroimmune cascade that recruits stem cells for tissue repair.

Glucosylglycerol serves as an active ingredient in ophthalmic formulations to protect the keratoconjunctiva from drying.

Administering tramadol before plasma exchange blocks NMDA receptors to enhance antibody removal.

Silvestrol targets host eIF4A helicase to block cap-dependent translation in RNA viruses like Ebola and Coronaviruses.

CERT S132A overexpression in CHO cells resolves the trade-off between high protein secretion and cell growth inhibition.

Formula I compounds with specific heterocyclic moieties overcome bacterial resistance mechanisms while maintaining treatment effectiveness.

Novel sotagliflozin crystal forms address poor stability under high water activity by modifying solvent systems to achieve uniform particle morphology.

Novel KRAS inhibitors target G12D mutants via localized chemical features, resolving selectivity and oral bioavailability trade-offs.

Novel pyrazolo[3,4-d]pyrimidine compounds target Wee1 kinase to induce apoptosis in p53-deficient tumors while improving clinical selectivity.

A melt-processed dosage form using tocopheryl compounds and propylene glycol fatty acid monoesters prevents drug recrystallization to enhance bioavailability.